Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03007329
Other study ID # ESR-15-10882
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 8, 2017
Est. completion date January 16, 2020

Study information

Verified date April 2022
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

SGLT2 antagonists and GLP1 agonists are used since a relatively short period as second line therapy if indicated and are well tolerated by patients featuring low risk of hypoglycaemia in comparison to insulin or other oral glucose lowering drug. This new treatment options offer an effective modality to lower blood glucose, if first line therapeutics fail. According to national and international guidelines combination of oral glucose lowering drugs is possible in multiple ways, but is currently not recommended for GLP1 agonists and SGLT2 inhibitors yet, as evidence and supporting studies are missing proving efficacy and safety]. Thus studies under standardized conditions are urgently needed to answer these unsolved questions. First results of a combination of a SGLT2 Inhibitor and a GLP1 agonist demonstrated huge potential regarding glucose and weight reduction and safety issues. However, further studies are necessary to elucidate potential mechanisms of combination therapy with SGLT2 inhibitors and GLP1 agonists and its effect on weight loss, glucose control, effects on incretins and adipokines, as well as further effects on ectopic lipid accumulation in liver and other tissues as myocard or pancreas in humans. As both monotherapies have effects on weight and metabolism, changes in abdominal, subcutaneous, hepatic, myocardial or pancreatic lipid content might be speculated and are focus of interest in this study. Recently GLP1 agonists were shown to have effects on hepatic lipid reduction in humans with diabetes. Hepatic lipid content and steatosis hepatis are widely discussed to have major effects on progression of diabetes and cardiovascular disease. Thus reduction of lipid accumulation in hepatic tissue might have an effect on diabetes progression. Also higher myocardial lipid accumulation is seen in diabetic patients probably partly responsible for higher cardiovascular risk in diabetics. So far results combining these two drug classes show less weight loss as might have been expected using monotherapy, so that further investigation will definitely shed light on combination of therapeutic concepts. Facing a multiple of positive side effects (weight loss, blood pressure lowering, potential protective cardiac effects) using a combination of SGLT2 and GLP1 seems to be a promising therapeutic option in diabetic subjects.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date January 16, 2020
Est. primary completion date November 26, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: T2DM - Sex: male and female - HbA1c >=6.5 and <=11 - Age >=18 and <=75 years - BMI>=25kg/m2 - Metformin>=1000mg daily, 8 weeks stable dose Please note: Type 2 diabetes mellitus patients treated with less than 1000 mg metformin per day can only be included if the investigator considers the patient to be on the maximum tolerated dose and the investigator has documented the reason why uptitration to 1000 mg was not possible - able and willing to not change diet and physical activity during enrollment in study - consent and able to give informed consent. Exclusion Criteria: - other diabetes diagnosis than T2DM - patients on other antidiabetic medication (Sulfonylurea, Glitazone, insulin for more than 2 weeks (see below), SGLT2 inhibitors, GLP1 agonist, nateglinide, repaglinide, acarbose, DPP4 inhibitors) - Subjects currently or previously treated with insulin (with the exception of emergency situations in which insulin was given for less than 14 consecutive days, but not within the last 3 months before screening) - known intolerance against study medication - Contraindications including hypersensitivity known to metformin according to the local label - recurrent urinary tract infections - GFR < 60 - Liver enzymes above 3 fold normal range - Bilirubin higher 3 fold normal range - Any other clinical condition that would jeopardize patients safety while participating in this clinical trial - disease at screening (other than NAFLD) such as relevant cardiovascular, gastrointestinal, hepatic, neurologic, psychiatric, endocrine (i.e. pancreatic) except T2DM, hematologic, malignant, infection or other major systemic diseases making implementation of the protocol or interpretation of the study results difficult - history of pancreatitis - Known autoimmune disease or chronic inflammatory condition - Myocardial infarction or stroke within 6 months prior to screening - Blood dyscrasias or any disorders causing haemolysis or unstable Red Blood Cell (e.g.malaria, babesiosis, haemolytic anaemia) - Other liver disease including chronic viral hepatitis (B or C), alcohol abuse, hemochromatosis, alpha-1antitrypsin deficiency, autoimmune hepatitis, Wilson's disease, primary sclerosing cholangitis or primary biliary cirrhosis, or liver cirrhosis of any etiology - malignancy within the last 5 years before randomisation - medullary thyroid cancer - family history of multiple endocrine neoplasia syndrome - Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake - Presence of any absolute or relative contraindication for the conduct of an MRI investigation, such as cardiac pacemakers, ferromagnetic haemostatic clips in the central nervous system, metallic splinters in the eye, ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators,cochlear implants, insulin pumps and nerve stimulators, prosthetic heart valves etc. - History of bariatric surgery - Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight - Subjects receiving antihypertensive medication and/or thyroid hormones, the dose(s) of which have not been stable for at least 6 weeks prior to baseline - Current treatment with systemic steroids at time of informed consent (Treatment with local and inhaled steroids is allowed) - Use of drugs potentially associated with NAFLD for more than 2 consecutive weeks in the 6 months prior to screening. - Use of anti-NASH drugs (thiazolidinediones, vitamin E, UDCA, SAM-e, betaine, milk thistle, anti-TNF therapies,) in the 3 months prior to randomization. - Donation of blood (> 400 mL) during the previous 3 months prior to the screening visit or during the duration of the study - Participation in another trial with an investigational drug within 30 days prior to informed consent. - Any subject who is the investigator or any coinvestigator, research assistant, pharmacist, study coordinator, other staff thereof, directly involved in the conduct of the protocol. - Pre-menopausal women (last menstruation =1 year prior to informed consent) who: - are nursing or pregnant or - are of child-bearing potential and are not practising an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives,sexual abstinence,( if acceptable by local authorities) double barrier method and vasectomised partner.

Study Design


Intervention

Drug:
Exenatide
Exenatide will be combined with Dapagliflozin
Exenatide matching Placebo
Exenatide matching Placebo will be combined with Dapagliflozin
Dapagliflozin
Dapagliflozin, in both arms

Locations

Country Name City State
Austria Abt. für Endokrinologie & Stoffwechsel, Univ. Klin f. Innere Medizin III Wien

Sponsors (2)

Lead Sponsor Collaborator
Medical University of Vienna AstraZeneca

Country where clinical trial is conducted

Austria, 

References & Publications (1)

Harreiter J, Just I, Leutner M, Bastian M, Brath H, Schelkshorn C, Klepochova R, Krššák M, Kautzky-Willer A. Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients wi — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other weight change in weight from baseline baseline - week 24
Other hip circumference change in hip circumference from baseline baseline - week 24
Other waist circumference change in waist circumference from baseline baseline - week 24
Other fasting glucose change in fasting plasma glucose from baseline baseline - week 24
Other HbA1c reduction >= 0.5% % of patient with HbA1c reduction of more than 0.5% baseline - week 24
Other weight reduction >= 5% % of patient with weight reduction of more than 5% baseline - week 24
Other change in triglycerides change in triglycerides from baseline baseline - week 24
Other change in cholesterol change in cholesterol from baseline baseline - week 24
Primary change in hepatic lipid content measured with magnetic resonance spectroscopy in % to investigate the effects on hepatic lipid content reduction of combination therapy with dapagliflozin (10mg daily) and exenatide (2mg weekly) compared to dapagliflozin (10mg daily) and placebo given for 24 weeks in patients with type 2 diabetes mellitus and insufficient glycaemic control despite oral therapy. baseline - week 24
Secondary change in myocardial lipid content measured with magnetic resonance spectroscopy in % to investigate the effects on myocardial lipid content reduction of combination therapy with dapagliflozin (10mg daily) and exenatide (2mg weekly) compared to dapagliflozin (10mg daily) and placebo given for 24 weeks in patients with type 2 diabetes mellitus and insufficient glycaemic control despite oral therapy. baseline - week 24
Secondary change in pancreatic lipid content measured with magnetic resonance spectroscopy in % to investigate the effects on pancreatic lipid content reduction of combination therapy with dapagliflozin (10mg daily) and exenatide (2mg weekly) compared to dapagliflozin (10mg daily) and placebo given for 24 weeks in patients with type 2 diabetes mellitus and insufficient glycaemic control despite oral therapy. baseline - week 24
Secondary Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 safety and tolerability from baseline to end by number of participants with treatment related AEs and SAEs baseline- week 24
Secondary Quality of Life questionnaire change from baseline in quality of live assessed by WHO Well Being Index baseline - week 24
Secondary change in insulin resistance change from baseline in insulin resistance assessed by HOMA IR Index baseline - week 24
Secondary change in insulin sensitivity change from baseline in insulin sensitivity assessed by OGIS baseline - week 24
Secondary energy expenditure change from baseline of energy expenditure assessed by indirect calorimetry baseline -week 24
Secondary energy intake change from baseline of energy intake assessed by 3 day eating protocols baseline -week 24
Secondary blood pressure To assess the effect of combination therapy with dapagliflozin and exenatide on blood pressure compared to dapagliflozin and placebo. baseline - week 24
Secondary weight loss To assess the effect of combination therapy with dapagliflozin and exenatide on weight loss compared to dapagliflozin and placebo. baseline - week 24.
Secondary change in glomerular filtration rate change in GFR from baseline baseline -week 24
See also
  Status Clinical Trial Phase
Recruiting NCT03239366 - A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population Phase 2
Completed NCT04597229 - Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus N/A
Completed NCT03623139 - Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes N/A
Active, not recruiting NCT04599920 - Effects of Replacing Red Meat With Legumes on Biomarkers of Chronic Diseases in Healthy Men (Leg4Life) N/A
Active, not recruiting NCT03422471 - Hypoglycemia and Autonomic Nervous System Function- B2 N/A
Completed NCT04382521 - A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions N/A
Recruiting NCT04564391 - Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins N/A
Recruiting NCT03458715 - The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin Phase 4
Terminated NCT03278236 - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men? N/A
Completed NCT02974504 - Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN) Phase 4
Completed NCT05053828 - Type 2 Diabetes With Antiplatelet Drugs
Not yet recruiting NCT03659383 - The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine Phase 4
Completed NCT03542240 - Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome N/A
Completed NCT03657537 - Effects of Ketone Bodies on Cognition in Type 2 Diabetes Phase 1
Completed NCT03979768 - Risk Assessment of Type 2 Diabetes in Pharmacies N/A
Completed NCT03614039 - Effect of Probiotic and Smectite Gel on NAFLD N/A
Active, not recruiting NCT04994288 - A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients Phase 2/Phase 3
Completed NCT03290768 - Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3) N/A
Enrolling by invitation NCT04088851 - "The Role of the Liver for Interorgan Metabolic Crosstalk in Type 2 Diabetes" N/A
Completed NCT03643783 - Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients